33462142|t|Estrogen receptor beta signaling in CD8+ T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch.
33462142|a|BackgroundThe non-overlapping functions of the two estrogen receptor subtypes, ERalpha (Estrogen Receptor alpha)and ERbeta (Estrogen Receptor beta), in tumor cells have been studied extensively. However, their counterparts in host cells is vastly underinterrogated. Even less is known about how ERalpha and ERbeta activities are regulated in a subtype-specific manner. We previously identified a phosphotyrosine residue (pY36) of human ERbeta that is important for tumor ERbeta to inhibit growth of breast cancer cells in vitro and in vivo. A role of this ERbeta phosphotyrosine switch in regulating host ERbeta remains unclear.Conventional gene editing was used to mutate the corresponding tyrosine residue of endogenous mouse ERbeta (Y55F) in mouse embryonic stem cells. The derived homozygous mutant Esr2Y55F/Y55F mouse strain and its wild-type (WT) counterpart were compared in various transplant tumor models for their ability to support tumor growth. In addition, flow cytometry-based immunophenotyping was carried out to assess antitumor immunity of WT and mutant hosts. Adoptive transfer of bone marrow and purified CD8+ T cells were performed to identify the host cell type that harbors ERbeta-dependent antitumor function. Furthermore, cell signaling assays were conducted to compare T cell receptor (TCR)-initiated signaling cascade in CD8+ T cells of WT and mutant mice. Lastly, the ERbeta-selective agonist S-equol was evaluated for its efficacy to boost immune checkpoint blockade (ICB)-based anticancer immunotherapy.Disabling the ERbeta-specific phosphotyrosine switch in tumor-bearing hosts exacerbates tumor growth. Further, a cell-autonomous ERbeta function was defined in CD8+ effector T cells. Mechanistically, TCR activation triggers ERbeta phosphorylation, which in turn augments the downstream TCR signaling cascade via a non-genomic action of ERbeta. S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Our findings support the development of ERbeta agonists including S-equol in combination with ICB immunotherapy for cancer treatment.
33462142	0	22	Estrogen receptor beta	Gene	13983
33462142	56	71	T cell receptor	Gene	328483
33462142	116	131	phosphotyrosine	Chemical	MESH:D019000
33462142	191	208	estrogen receptor	Gene	2099
33462142	219	226	ERalpha	Gene	2099
33462142	228	251	Estrogen Receptor alpha	Gene	13982
33462142	256	262	ERbeta	Gene	13983
33462142	264	286	Estrogen Receptor beta	Gene	13983
33462142	292	297	tumor	Disease	MESH:D009369
33462142	435	442	ERalpha	Gene	13982
33462142	447	453	ERbeta	Gene	13983
33462142	536	551	phosphotyrosine	Chemical	MESH:D019000
33462142	570	575	human	Species	9606
33462142	576	582	ERbeta	Gene	2100
33462142	605	610	tumor	Disease	MESH:D009369
33462142	611	617	ERbeta	Gene	2100
33462142	639	652	breast cancer	Disease	MESH:D001943
33462142	696	702	ERbeta	Gene	13983
33462142	703	718	phosphotyrosine	Chemical	MESH:D019000
33462142	745	751	ERbeta	Gene	13983
33462142	862	867	mouse	Species	10090
33462142	868	874	ERbeta	Gene	13983
33462142	876	880	Y55F	ProteinMutation	tmVar:p|SUB|Y|55|F;HGVS:p.Y55F;VariantGroup:0;OriginalGene:13983;CorrespondingGene:2100;CorrespondingSpecies:10090
33462142	885	890	mouse	Species	10090
33462142	952	956	Y55F	ProteinMutation	tmVar:p|SUB|Y|55|F;HGVS:p.Y55F;VariantGroup:0;OriginalGene:13983;CorrespondingGene:2100;CorrespondingSpecies:10090
33462142	957	962	mouse	Species	10090
33462142	1041	1046	tumor	Disease	MESH:D009369
33462142	1083	1088	tumor	Disease	MESH:D009369
33462142	1336	1342	ERbeta	Gene	13983
33462142	1434	1449	T cell receptor	Gene	328483
33462142	1451	1454	TCR	Gene	328483
33462142	1517	1521	mice	Species	10090
33462142	1535	1541	ERbeta	Gene	13983
33462142	1560	1567	S-equol	Chemical	MESH:D060754
33462142	1686	1692	ERbeta	Gene	13983
33462142	1702	1717	phosphotyrosine	Chemical	MESH:D019000
33462142	1728	1733	tumor	Disease	MESH:D009369
33462142	1760	1765	tumor	Disease	MESH:D009369
33462142	1801	1807	ERbeta	Gene	13983
33462142	1872	1875	TCR	Gene	328483
33462142	1896	1902	ERbeta	Gene	13983
33462142	1958	1961	TCR	Gene	328483
33462142	2008	2014	ERbeta	Gene	13983
33462142	2016	2023	S-equol	Chemical	MESH:D060754
33462142	2036	2039	TCR	Gene	328483
33462142	2071	2077	ERbeta	Gene	13983
33462142	2078	2093	phosphotyrosine	Chemical	MESH:D019000
33462142	2117	2121	PD-1	Gene	18566
33462142	2123	2154	Programmed cell death protein 1	Gene	18566
33462142	2178	2183	mouse	Species	10090
33462142	2233	2239	ERbeta	Gene	13983
33462142	2240	2255	phosphotyrosine	Chemical	MESH:D019000
33462142	2277	2283	ERbeta	Gene	13983
33462142	2370	2376	ERbeta	Gene	13983
33462142	2396	2403	S-equol	Chemical	MESH:D060754
33462142	2446	2452	cancer	Disease	MESH:D009369
33462142	Association	MESH:D019000	2100
33462142	Association	MESH:D009369	13983
33462142	Association	MESH:D060754	13983
33462142	Association	MESH:D009369	13982
33462142	Association	MESH:D019000	328483
33462142	Association	MESH:D009369	HGVS:p.Y55F;CorrespondingGene:2100
33462142	Negative_Correlation	MESH:D001943	2100
33462142	Positive_Correlation	MESH:D060754	328483
33462142	Association	MESH:D019000	13983
33462142	Positive_Correlation	13983	328483
33462142	Association	MESH:D019000	MESH:D009369
33462142	Association	MESH:D009369	2099
33462142	Positive_Correlation	MESH:D060754	18566
33462142	Association	MESH:D019000	MESH:D060754
33462142	Association	MESH:D009369	2100
33462142	Association	13983	18566
33462142	Positive_Correlation	2100	328483
33462142	Negative_Correlation	MESH:D019000	MESH:D001943
33462142	Association	MESH:D009369	2100

